Development and Validation of a High-Performance Liquid Chromatography Method to Quantify Marker Compounds in Lysimachia vulgaris var. davurica and Its Effects in Diarrhea-Predominant Irritable Bowel Syndrome. [PDF]
Kim HY +5 more
europepmc +1 more source
Related searches:
Emerging Drug for Diarrhea Predominant Irritable Bowel Syndrome
Expert Opinion on Emerging Drugs, 2015Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders with a 9 - 23% prevalence estimated in the general population. Patients can be subdivided into those who tend to have predominant diarrhea (IBS-D) or predominant constipation (IBS-C). Total annual productivity loss related to IBS in US is estimated at $205 million, with
Tommaso Gabbani +2 more
exaly +3 more sources
Advancements in Drug Development for Diarrhea-Predominant Irritable Bowel Syndrome
Expert Opinion on Investigational Drugs, 2018Diarrhea-predominant irritable bowel syndrome (IBS-D) is a common disorder characterized by a complex pathophysiology hampering optimal targeted drug development. Recent advances in our understanding of key underlying mechanisms prompted novel therapeutics including novel pharmacological approaches.This review summarizes the latest advancements in the ...
Giovanni Barbara +2 more
exaly +3 more sources
Rifaximin for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
Expert Review of Gastroenterology and Hepatology, 2016Irritable bowel syndrome (IBS) is a chronic, functional bowel disorder characterized by abdominal pain or discomfort and altered bowel habit. The pathophysiology is unclear, but may include altered gut motility, visceral hypersensitivity, abnormal central pain processing, chronic low-grade intestinal inflammation, or disturbances in the gut microbiome.
Alexander C. Ford, John S Kane
exaly +3 more sources
Medical Therapies for Diarrhea-Predominant Irritable Bowel Syndrome
Gastroenterology Clinics of North America, 2021Diarrhea-predominant irritable bowel syndrome is a common functional gastrointestinal disorder that manifests with abdominal pain and diarrheal bowel patterns, without structural explanation. Diarrhea-predominant irritable bowel syndrome is a heterogeneous condition resulting from diverse pathophysiologic processes.
openaire +2 more sources
Serotonin-Transporter Polymorphism Pharmacogenetics in Diarrhea-Predominant Irritable Bowel Syndrome
Gastroenterology, 2002A serotonin (5-HT)(3) receptor antagonist relieves symptoms in women with diarrhea-predominant irritable bowel syndrome (D-IBS). 5-HT undergoes reuptake by a transporter protein (SERT). Polymorphisms in the promoter for synthesis of SERT (SERT-P) influence response to serotonergic medications in depression.
Michael Camilleri, Sanna McKinzie
exaly +3 more sources
[Diarrhea predominant irritable bowel syndrome].
La Revue du praticien, 2008The diagnosis of diarrhea predominant irritable bowel syndrome (D-IBS) should be a positive diagnosis, based on Rome criteria, and not a diagnosis of exclusion. However, it is in this situation that investigations are frequently performed. But full and complete explorations are not systematically required as they are frequently normal, and normal ...
Jean-Marc, Sabaté, Benoît, Coffin
openaire +1 more source
Evaluation of Crofelemer in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome Patients
Digestion, 2008Background: Crofelemer improves bowel function in several conditions characterized by states of prominent secretory diarrhea. Aim: This double-blind, randomized, placebo-controlled trial evaluated the effects of 3 dose levels of crofelemer in patients with diarrhea-predominant irritable bowel syndrome (D-IBS).
Allen W, Mangel, Pravin, Chaturvedi
openaire +2 more sources
Abnormal Intestinal Permeability in Subgroups of Diarrhea-Predominant Irritable Bowel Syndromes
The American Journal of Gastroenterology, 2006Irritable bowel syndrome (IBS) is a heterogeneous condition and defined according to symptoms. Low-grade inflammation has been associated with IBS, particularly that following infection, but whether altered intestinal permeability profiles relate to irritable bowel subtype or onset is uncertain.
Simon P, Dunlop +6 more
openaire +2 more sources
Cilansetron in the treatment of diarrhea-predominant irritable bowel syndrome?
Expert Review of Gastroenterology & Hepatology, 2007Information on the 5-hydroxytryptamine type 3 receptor antagonist cilansetron is scarce and most studies have only been published in abstract form. Results from preclinical and two dose-finding studies have suggested that cilansetron could be effective in the treatment of patients with diarrhea-predominant irritable bowel syndrome.
openaire +2 more sources

